IRLAB’s rights issue is registered – conversion of BTA into shares

July 10, 2026

IRLAB Therapeutics AB’s (the “Company”) rights issue of ordinary shares of series A, which the Board of Directors resolved on 5 May 2026 and was approved by the Extraordinary General Meeting on 5 June 2026, is registered with the Swedish Companies Registration Office. Paid subscribed shares (“BTA”) will therefore be converted into ordinary shares of series A.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.

IRLAB Therapeutics AB’s (the “Company”) rights issue of ordinary shares of series A, which the Board of Directors resolved on 5 May 2026 and was approved by the Extraordinary General Meeting on 5 June 2026, is registered with the Swedish Companies Registration Office. Paid subscribed shares (“BTA”) will therefore be converted into ordinary shares of series A.

The last day for trading in BTA on Nasdaq Stockholm is 15 July 2026 and the record date with Euroclear Sweden AB for the conversion of BTA into ordinary shares of series A is 17 July 2026. The newly issued ordinary shares of series A are expected to be booked into each holder’s securities account/VP-account on 21 July 2026.

Advisers
MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue. Aqurat Fondkommission AB is issuing agent in connection with the Rights Issue.